Cinnolin-2-oxid | 4215-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Cinnolin-2-oxid
• 英文别名: Cinnoline 2-oxide；2-oxidocinnolin-2-ium
• CAS: 4215-44-5
• 化学式: C₈H₆N₂O
• 分子量: 146.148
• InChiKey: AJWWAZZHNBBRPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  正丙胺 、 Cinnolin-2-oxid 在 bis(pyridine)silver(I) permanganate 作用下， 反应 480.0h， 以60%的产率得到Cinnolin-3-yl-propyl-amine
  参考文献：
  名称：

  Cinnoline，Cinnoline N-氧化物及其氯代衍生物与烷基胺的反应：Cinnoline系列中氢亲核取代的第一例

  摘要：

  DOI：

  10.1023/a:1023076810168

文献信息

• [EN] 1,3-DIHYDROIMIDAZO[4,5-C]CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS 1,3-DIHYDROIMIDAZO[4,5-C]CINNOLIN-2-ONE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2019057757A1

  公开（公告）日：2019-03-28

  The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1-R4, A and X have the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted 1,3-dihydroimidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof; and kits comprising such compounds and salts.

  该规范通常涉及公式（I）的化合物及其药用可接受的盐，其中R1-R4、A和X的含义在此定义。该规范还涉及使用公式（I）的化合物及其盐来治疗或预防ATM介导的疾病，包括癌症。该规范还涉及包含取代的1,3-二氢咪唑并[4,5-c]茚啉-2-酮化合物及其药用可接受的盐的药物组合物；以及包含这些化合物和盐的试剂盒。
• Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
  申请人：Lim Mu'Ill

  公开号：US20060156485A1

  公开（公告）日：2006-07-20

  Compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and at least one bicyclic 6-6 (0:1, 0:2, 1:1, 1:2) aza heteroaromatic keratin dyeing compound with one or two N-oxides. A method for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period sufficient to develop the desired coloration.

  用于氧化染色角蛋白纤维的组合物，包括适合染色的介质和至少一种含有一个或两个N-氧化物的双环6-6（0:1, 0:2, 1:1, 1:2）杂环芳香族角蛋白染色化合物。一种氧化染色角蛋白纤维的方法，包括在氧化剂存在下施用这种组合物，以足够时间发展所需的着色。
• [EN] SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF<br/>[FR] MODULATEURS SÉLECTIFS DE LA KINASE ATAXIE TÉLANGIECTASIE MUTÉE (ATM) ET LEURS UTILISATIONS
  申请人：SUZHOU ZANRONG PHARMA LTD

  公开号：WO2022194138A1

  公开（公告）日：2022-09-22

  The specification relates to imidazo [4,5-c] cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated ("ATM") kinase. The specification also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers.

  该规范涉及咪唑[4,5-c]茚并[2H]喹唑-2-酮化合物及其药学上可接受的盐，这些化合物可以选择性地调节共济失调毛细血管扩张性变异蛋白激酶（“ATM”）。该规范还涉及制药组合物，其包含一个或多个该化合物及其盐作为活性成分，以及在治疗ATM相关疾病或病症，包括癌症中使用该化合物及其盐的用途。
• 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-C] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
  申请人：Suzhou Zanrong Pharma Limited

  公开号：EP3849984A1

  公开（公告）日：2021-07-21
• [EN] 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF<br/>[FR] 1-ISOPROPYL-3-MÉTHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-C] CINNOLIN-2-ONE SERVANT DE MODULATEURS SÉLECTIFS DE LA KINASE ATAXIE TÉLANGIECTASIE (ATM) MUTÉE ET UTILISATIONS ASSOCIÉES
  申请人：SUZHOU ZANRONG PHARMA LTD

  公开号：WO2020052688A1

  公开（公告）日：2020-03-19

  The present application discloses novel substituted imidazo [4, 5-c] cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated ( "ATM" ) kinase. The present application also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers.